NICE Wants More Evidence To Clear Janssen’s Velcade For Multiple Myeloma
This article was originally published in The Pink Sheet Daily
Executive Summary
The British HTA NICE wants more clinical and cost-effectiveness data on Janssen’s Velcade in combination therapy before clearing it for battle with thalidomide for multiple myeloma.